A case-control study of high-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection in the treatment of uterine fibroids.
The purpose of this study was to explore the feasibility of high-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection in the treatment of uterine fibroids and to compare its therapeutic effects and potential side effects with those of simple high-intensity focused ultrasound treatment. Forty patients with uterine fibroids from the Department of Ultrasonography in our hospital were randomly divided into 2 groups of the same size: group H, which only underwent high-intensity focused ultrasound treatment; and group H + A, which underwent sonographically guided intratumoral ethanol injection therapy first and then high-intensity focused ultrasound treatment the following day. The treatment times, treatment doses, pain scores, side effects, and therapeutic effect rates of the groups were then recorded and compared. Both the treatment time and dose of group H + A were significantly less than those of group H, and the differences were statistically significant (P < .05). A lower pain score and fewer side effects were achieved in group H + A, also with statistically significant differences (P < .05). The therapeutic effect rate of group H + A was also higher than that of group H, and the difference was also statistically significant (P < .05). In the treatment of uterine fibroids, high-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection requires less treatment time and a lower dose than simple high-intensity focused ultrasound treatment and significantly reduces the pain and side effects commonly experienced by patients. High-intensity focused ultrasound combined with sonographically guided intratumoral ethanol injection is a feasible, safe, and more effective way to treat patients with uterine fibroids.